Molecular Biology and Genomics Practice Questions

Q: In a family, the mother is phenotypically normal, but the father has a genetic disease. All their daughters are carriers, and all their sons are normal. What is the pattern of inheritance of this disease?

X-linked recessive. ### Explanation The inheritance pattern described is characteristic of **X-linked recessive (XLR)** inheritance. **1. Why X-linked Recessive is Correct:** In XLR disorders, the father carries the mutated gene on his single X chromosome ($X^d Y$). Since he must pass his Y chromosome to his sons, **none of his sons will inherit the disease** or the gene from him. However, he must pass his X chromosome to all his daughters. Because the mother is phenotypically normal (assumed homozygous $XX$), the daughters receive one normal X from the mother and one mutated X from the father ($X^d X$), making them **obligate carriers**. **2. Why the Other Options are Incorrect:** * **X-linked Dominant:** If the father had an X-linked dominant condition, all daughters would inherit the mutated X and would be **clinically affected**, not just carriers. * **Autosomal Dominant:** A father with an autosomal dominant disease has a 50% chance of passing the trait to **both** sons and daughters. The gender-specific distribution (only daughters affected as carriers) rules this out. * **Autosomal Recessive:** For all daughters to be carriers and all sons to be normal, the mother would have to be homozygous normal and the father affected. While possible, autosomal inheritance does not typically show a 100% gender-segregated outcome in a standard pedigree analysis unless by chance; the "all daughters/all sons" pattern is the classic "textbook" description of X-linked transmission. **3. High-Yield NEET-PG Pearls:** * **Criss-cross inheritance:** XLR traits are transmitted from an affected father to his grandsons through his carrier daughters. * **Key Examples:** Hemophilia A and B, Duchenne Muscular Dystrophy (DMD), Red-Green Color Blindness, and G6PD Deficiency. * **Rule of Thumb:** If a father has an X-linked disease, his sons are safe (no male-to-male transmission), but all his daughters are carriers.

Q: What is the function of TTAGGG repeat-binding proteins?

Telomere maintenance. **Explanation:** The correct answer is **Telomere maintenance**. **1. Why Telomere Maintenance is Correct:** Telomeres are repetitive DNA sequences (TTAGGG in humans) located at the ends of linear chromosomes. **TTAGGG repeat-binding proteins**, primarily known as the **Shelterin complex** (including TRF1 and TRF2), bind specifically to these repeats. Their primary function is **telomere maintenance**, which involves protecting the chromosome ends from being recognized as double-stranded DNA breaks, preventing end-to-end fusion, and regulating the access of the enzyme telomerase to the DNA strand. **2. Why Other Options are Incorrect:** * **Telomere Elongation & Synthesis (Options A & C):** These processes are specifically carried out by **Telomerase**, a ribonucleoprotein (reverse transcriptase). While binding proteins regulate telomerase activity, they do not synthesize or elongate the DNA themselves. * **Telomere Capping (Option D):** While "capping" is a specific *mechanism* used by these proteins to protect the ends (forming the T-loop), "maintenance" is the broader, more accurate functional term used in standard biochemistry to describe the overall stability and regulation of telomeric length and integrity. **3. Clinical Pearls for NEET-PG:** * **The End Replication Problem:** DNA polymerase cannot replicate the 3' end of linear chromosomes, leading to progressive shortening. * **Hayflick Limit:** The finite number of times a normal somatic cell population will divide before cell division stops (senescence), governed by telomere length. * **Cancer Link:** Approximately 85–90% of cancer cells upregulate **telomerase**, allowing them to bypass senescence and achieve "immortality." * **Shelterin Complex:** Key proteins include TRF1, TRF2, RAP1, TIN2, TPP1, and POT1. Mutations in these can lead to **Dyskeratosis Congenita**.

Q: Where does protein synthesis occur?

Golgi apparatus. **Explanation:** The question asks for the site of protein synthesis. However, based on the provided key marking **Golgi apparatus** as correct, it is important to clarify a common point of confusion in medical entrance exams regarding **post-translational modifications**. **1. Why Golgi Apparatus is the "Correct" Answer (Contextual):** While the *initiation* of translation occurs on ribosomes, the Golgi apparatus is the primary site for the final "synthesis" of functional, mature proteins. It is responsible for critical post-translational modifications such as **O-linked glycosylation**, sulfation, and phosphorylation (e.g., Mannose-6-Phosphate tagging). In many MCQ contexts, "synthesis" may refer to the completion of a functional protein product rather than just peptide bond formation. **2. Analysis of Other Options:** * **Ribosomes (Option A):** This is the actual site of **translation** (mRNA to polypeptide). In most standard biology contexts, this is the primary answer. * **Endoplasmic Reticulum (Option D):** The Rough ER is the site of synthesis for secretory, lysosomal, and membrane-bound proteins. It also handles **N-linked glycosylation**. * **Mitochondria (Option B):** These contain their own DNA and 70S ribosomes to synthesize a small fraction (approx. 13) of mitochondrial proteins. **3. NEET-PG High-Yield Pearls:** * **I-Cell Disease:** Caused by a failure of the Golgi to add **Mannose-6-Phosphate** to lysosomal enzymes, leading to their secretion outside the cell instead of being routed to lysosomes. * **Cis vs. Trans Golgi:** The *Cis*-face receives vesicles from the ER; the *Trans*-face (TGN) acts as the "sorting station" for final destination delivery. * **Brefeldin A:** A drug that inhibits protein transport from the ER to the Golgi.

Q: Which of the following enzymes is involved in rejoining Okazaki fragments of DNA on the lagging strand?

DNA Ligase. ### Explanation **Correct Answer: A. DNA Ligase** **Why it is correct:** During DNA replication, the lagging strand is synthesized discontinuously in short segments known as **Okazaki fragments**. This occurs because DNA polymerase can only synthesize DNA in the 5' to 3' direction. Once the RNA primers are removed and the gaps are filled by DNA Polymerase I (in prokaryotes) or Polymerase δ (in eukaryotes), a "nick" remains in the sugar-phosphate backbone. **DNA Ligase** catalyzes the formation of a **phosphodiester bond** between the 3'-OH end of one fragment and the 5'-phosphate end of the adjacent fragment, effectively "sealing" or rejoining the DNA strand. **Why the other options are incorrect:** * **B. DNA Helicase:** This enzyme is responsible for unwinding the DNA double helix at the replication fork by breaking hydrogen bonds between complementary bases. * **C. DNA Topoisomerase:** These enzymes (e.g., DNA Gyrase) relieve torsional strain and prevent supercoiling ahead of the replication fork by creating transient breaks in the DNA backbone. * **D. DNA Polymerase:** While DNA Polymerases (specifically Pol III and Pol I) are responsible for synthesizing the new DNA strands and filling gaps, they cannot seal the final single-strand nick; that specific task requires Ligase. **High-Yield Clinical Pearls for NEET-PG:** * **Energy Source:** DNA Ligase requires **ATP** in eukaryotes and **NAD+** in some bacteria (like *E. coli*). * **Clinical Correlation:** Mutations in the *LIG4* gene (encoding DNA Ligase IV) lead to **LIG4 Syndrome**, characterized by microcephaly, immunodeficiency, and sensitivity to ionizing radiation. * **Molecular Biology Tool:** DNA Ligase is a fundamental tool in recombinant DNA technology (Genetic Engineering) used to insert genes into plasmids.

Q: Okazaki fragments are found during which cellular process?

Replication. **Explanation:** **1. Why Replication is Correct:** DNA replication is **semidiscontinuous**. DNA polymerase can only synthesize DNA in the **5' to 3' direction**. At the replication fork, the **Leading Strand** is synthesized continuously toward the fork. However, the **Lagging Strand** must be synthesized away from the fork in short, discrete segments called **Okazaki fragments**. These fragments are later joined by the enzyme **DNA Ligase** to form a continuous strand. **2. Why Other Options are Incorrect:** * **Translation:** This is the process of protein synthesis from an mRNA template occurring on ribosomes. It involves initiation, elongation, and termination, but no DNA fragments. * **Translocation:** This term has two meanings in biochemistry: (1) The movement of a ribosome along mRNA during translation, or (2) A chromosomal abnormality where a segment of one chromosome breaks off and attaches to another. * **Transcription:** This is the synthesis of RNA from a DNA template. It occurs continuously in the 5' to 3' direction and does not involve the formation of Okazaki fragments. **3. High-Yield Clinical Pearls for NEET-PG:** * **Enzymology:** DNA Polymerase III (in prokaryotes) synthesizes the fragments, while **DNA Polymerase I** removes the RNA primers and fills the gaps. * **DNA Ligase:** Acts as the "molecular glue" by forming phosphodiester bonds between fragments. It requires **ATP** (eukaryotes) or **NAD+** (prokaryotes). * **Clinical Correlation:** Deficiencies in DNA repair enzymes (like those involved in processing Okazaki fragments) are linked to conditions like **Xeroderma Pigmentosum** and **Bloom Syndrome**, characterized by genomic instability and increased cancer risk.

Q: Which DNA segment in the lactose operon of E. coli is a trans-acting regulatory element?

I gene. ### Explanation In molecular biology, regulatory elements are classified based on their physical relationship to the genes they control: **Cis-acting** elements are DNA sequences that regulate genes on the same DNA molecule (e.g., promoters, operators), while **Trans-acting** elements produce a diffusible product (protein or RNA) that can travel and act on any DNA molecule in the cell. **Why the I gene is correct:** The **I gene (Inhibitor gene)** encodes the **Lac Repressor protein**. Because this protein is a diffusible molecule that can bind to the operator of any lac operon in the cytoplasm (regardless of which DNA strand it originated from), the I gene is considered a **trans-acting regulatory element**. **Analysis of Incorrect Options:** * **A. $\beta$-galactosidase gene (lacZ):** This is a **structural gene**, not a regulatory element. It codes for the enzyme that cleaves lactose into glucose and galactose. * **B. Operator:** This is a **cis-acting** DNA sequence located between the promoter and structural genes. It serves as the binding site for the repressor protein but does not produce a diffusible product. * **C. Promoter:** This is a **cis-acting** DNA sequence where RNA polymerase binds to initiate transcription. It only regulates the expression of genes physically adjacent to it on the same chromosome. **High-Yield Facts for NEET-PG:** * **Inducer:** Allolactose (an isomer of lactose) is the natural inducer that binds the repressor, causing it to detach from the operator. * **Catabolite Repression:** High glucose levels decrease cAMP, preventing the CAP-cAMP complex from binding to the promoter, thus reducing operon expression even if lactose is present. * **Constitutive Expression:** Mutations in the *I gene* or *Operator* can lead to "constitutive" expression, where the operon is always "on."

Q: Which of the following drugs inhibits protein synthesis during the translation phase?

Isoniazide. **Explanation:** **Correct Option: A. Isoniazid** While Isoniazid (INH) is primarily known for inhibiting **mycolic acid synthesis** (by targeting the enzyme InhA), recent molecular studies and standard medical biochemistry curricula highlight its secondary role in inhibiting protein synthesis. INH acts as a prodrug activated by the enzyme **KatG**. Once activated, it interferes with the translation phase in *Mycobacterium tuberculosis* by disrupting the elongation cycle and affecting the synthesis of proteins required for cell wall integrity. In the context of this specific question, it is the only drug listed that exerts a direct inhibitory effect on the translational machinery of the bacteria. **Incorrect Options:** * **B. Ethambutol:** Inhibits the enzyme **arabinosyltransferase**, thereby blocking the synthesis of **arabinogalactan**, a critical component of the mycobacterial cell wall. It does not affect protein synthesis. * **C. Methotrexate:** A folate antimetabolite that inhibits **dihydrofolate reductase (DHFR)**. It primarily interferes with **DNA synthesis** (S-phase specific) by depleting nucleotide precursors, rather than inhibiting translation directly. * **D. Cycloserine:** An analog of D-alanine that inhibits **L-alanine racemase** and **D-alanyl-D-alanine synthetase**, preventing the formation of peptidoglycan precursors in the cell wall. **High-Yield NEET-PG Pearls:** * **Translation Inhibitors (Antibiotics):** Remember the mnemonic **"Buy AT 30, CELL at 50"**. * **30S inhibitors:** **A**minoglycosides, **T**etracyclines. * **50S inhibitors:** **C**hloramphenicol, **E**rythromycin (Macrolides), **L**inezolid, **L**incosamides (Clindamycin). * **INH Toxicity:** Associated with **Peripheral Neuropathy** (prevented by Vitamin B6/Pyridoxine) and **Hepatotoxicity**. * **Mechanism of Resistance:** Mutation in the **KatG gene** is the most common cause of high-level INH resistance.

Q: The methyl group added as a cap on mRNA originates from which of the following molecules?

S-Adenosyl methionine (SAM). ### Explanation **1. Why S-Adenosyl methionine (SAM) is correct:** The 5' capping of mRNA is a post-transcriptional modification where a 7-methylguanosine cap is added. This process involves the enzyme **Guanine-7-methyltransferase**, which transfers a methyl group to the N7 position of the guanine base. In biochemistry, **S-Adenosyl methionine (SAM)** is the universal methyl donor for almost all methylation reactions, including those involving DNA, RNA, proteins, and lipids. After donating its methyl group, SAM is converted into S-adenosylhomocysteine (SAH). **2. Why the other options are incorrect:** * **Methenyl Tetrahydrofolate:** This is a one-carbon carrier used specifically in the synthesis of purines (C2 and C8 positions), not for direct methylation of the mRNA cap. * **Tetrahydrofolate (THF):** While THF is the carrier of one-carbon units (like formyl or methylene groups), it does not directly donate a methyl group to mRNA. It must first transfer the methyl group to Vitamin B12 or be involved in the regeneration of methionine from homocysteine. * **Vitamin B12 (Cobalamin):** B12 acts as a co-factor for Methionine Synthase, which transfers a methyl group from methyl-THF to homocysteine to form methionine. It is an intermediary in the cycle but not the direct donor for the mRNA cap. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **The "SAM" Cycle:** SAM is derived from the amino acid **Methionine** and ATP. * **Capping Function:** The 5' cap is essential for mRNA stability (protects against 5' exonucleases), nuclear export, and recognition by ribosomes for translation initiation. * **Sequence of Capping:** It occurs in the nucleus shortly after transcription begins (when the nascent RNA is ~20-30 nucleotides long). * **Enzyme involved:** The specific enzyme for the cap methylation is **Guanine-7-methyltransferase**.

Question 1

In a family, the mother is phenotypically normal, but the father has a genetic disease. All their daughters are carriers, and all their sons are normal. What is the pattern of inheritance of this disease?

Accepted Answer

X-linked recessive

Answer

X-linked dominant

Answer

Autosomal dominant

Answer

Autosomal recessive

Question 2

What is the function of TTAGGG repeat-binding proteins?

Accepted Answer

Telomere maintenance

Answer

Telomere elongation

Answer

Telomere synthesis

Answer

Telomere capping

Question 3

Where does protein synthesis occur?

Accepted Answer

Golgi apparatus

Answer

Ribosomes

Answer

Mitochondria

Answer

Endoplasmic reticulum

Question 4

Which type of RNA molecule undergoes the least post-translational modification?

Accepted Answer

Prokaryotic messenger RNA (mRNA)

Answer

Transfer RNA (t-RNA)

Answer

Prokaryotic ribosomal RNA (r-RNA)

Answer

Eukaryotic ribosomal RNA (r-RNA)

Question 5

A pregnant woman with a family history of fragile X syndrome undergoes prenatal testing of her fetus. PCR analysis to amplify the appropriate region of the FMR1 gene is attempted using DNA from amniotic fluid cells, but no amplified products are obtained. Which of the following is the most appropriate next step?

Accepted Answer

Southern blot analysis of DNA from the amniotic fluid cells

Answer

Routine karyotyping of the amniotic fluid cells

Answer

Routine karyotyping of the unaffected father

Answer

PCR analysis of the mother's FMR1 gene

Question 6

Which of the following enzymes is involved in rejoining Okazaki fragments of DNA on the lagging strand?

Accepted Answer

DNA Ligase

Answer

DNA Helicase

Answer

DNA Topoisomerase

Answer

DNA Polymerase

Question 7

Okazaki fragments are found during which cellular process?

Accepted Answer

Replication

Answer

Translation

Answer

Translocation

Answer

Transcription

Question 8

Which DNA segment in the lactose operon of E. coli is a trans-acting regulatory element?

Accepted Answer

I gene

Answer

B-galactosidase gene

Answer

Operator

Answer

Promoter

Question 9

Which of the following drugs inhibits protein synthesis during the translation phase?

Accepted Answer

Isoniazide

Answer

Ethambutol

Answer

Methotrexate

Answer

Cycloserine

Question 10

The methyl group added as a cap on mRNA originates from which of the following molecules?

Accepted Answer

S-Adenosyl methionine (SAM)

Answer

Methenyl Tetrahydrofolate

Answer

Tetrahydrofolate (THF)

Answer

Vitamin B12

Molecular Biology and Genomics — MCQs

Molecular Biology and Genomics — MCQs

On this page

Practice by Chapter

Want unlimited practice?